A Phase 2b Randomized Controlled Double-blind Multicenter Study Comparing the Efficacy and Safety of Zetomipzomib (KZR-616) 30 mg or 60 mg with Placebo in Patients with Active Lupus Nephritis

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Lupus Nephritis
  • Age: Between 18 Year(s) - 89 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Has a body mass index of =18 kg/m2.
    2. Has a diagnosis of systemic lupus erythematosus (SLE).
    3. Has a diagnosis of III or IV LN as evidenced by renal biopsy performed within 12 months prior to or during Screening.

You may not be eligible for this study if the following are true:

    1. Has previously received zetomipzomib or previously enrolled in the study (patients may be rescreened once).
    2. Has had dialysis within the 52 weeks prior to Screening.
    3. Has active central nervous system manifestations resul


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.